Literature DB >> 26377157

Bombesin-conjugated nanoparticles improve the cytotoxic efficacy of docetaxel against gastrin-releasing but androgen-independent prostate cancer.

Hitesh Kulhari1,2,3,4, Deep Pooja2, Mayank K Singh2, Madhusudana Kuncha2, David J Adams3, Ramakrishna Sistla2.   

Abstract

AIM: Bombesin (BBN)-conjugated polymeric nanoparticles to target docetaxel (DTX) to prostate cancer cells that overexpress gastrin-releasing peptides receptors. MATERIALS &
METHODS: In vitro cytotoxicity, uptake of nanoparticles and inhibition of cell migration were assessed against human prostate cancer cells. Preclinical pharmacokinetic and tissue-distribution studies of nanoparticles were performed in Balb/c mice and results compared with the marketed formulation Taxotere(®).
RESULTS: BBN-conjugated DTX-loaded nanoparticles exhibited higher cytotoxicity, inhibition of cell migration and colony formation than non-targeted nanoparticles or DTX alone. More BBN-conjugated nanoparticles were taken up at a faster rate than unconjugated nanoparticles. In vivo, this drug delivery improved pharmacokinetics of DTX by increasing mean residence time and decreasing clearance.
CONCLUSION: This study provides an alternate approach for polysorbate-free delivery of DTX, with improved in vivo performance.

Entities:  

Keywords:  bombesin; cytotoxicity; docetaxel; nanoparticles; pharmacokinetics; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26377157     DOI: 10.2217/nnm.15.107

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  6 in total

Review 1.  Bombesin-drug conjugates in targeted therapy for small cell lung cancer.

Authors:  Yichi Zhang; Elizabeth Holland; Anna Dinh; Duc Au; Lichun Sun
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

2.  Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles.

Authors:  Amrita Kadari; Sagarika Gudem; Hitesh Kulhari; Murali Mohan Bhandi; Roshan M Borkar; Venkata Ramana Murthy Kolapalli; Ramakrishna Sistla
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer.

Authors:  Hitesh Kulhari; Deep Pooja; Shweta Shrivastava; Madhusudana Kuncha; V G M Naidu; Vipul Bansal; Ramakrishna Sistla; David J Adams
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

Review 4.  Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.

Authors:  Mahjabin Khan; Tao Huang; Cheng-Yuan Lin; Jiang Wu; Bao-Min Fan; Zhao-Xiang Bian
Journal:  Oncotarget       Date:  2017-06-07

5.  68Ga-radiolabeled bombesin-conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: preparation, characterization and biological evaluation.

Authors:  Maliheh Hajiramezanali; Fatemeh Atyabi; Mona Mosayebnia; Mehdi Akhlaghi; Parham Geramifar; Amir Reza Jalilian; Seyed Mohammad Mazidi; Hassan Yousefnia; Soraya Shahhosseini; Davood Beiki
Journal:  Int J Nanomedicine       Date:  2019-04-10

Review 6.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.